<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ELLA- ulipristal acetateÂ tabletÂ </strong><br>Afaxys Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use ella safety and effectively. See full prescribing information for ella.<br><br>ellaÂ (ulipristal acetate) tablet</span><br><span class="Bold">Initial U.S. Approval: 2010</span>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><ul><li>Warnings and Precautions, CYP3A4 Inducers (<a href="#Lb8a6e9b5-c492-42e5-a7c1-d56de1ae1426">5.4</a>) 6/2014</li></ul></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"><span class="Bold">ella</span> is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. <span class="Bold">ella</span> is not intended for routine use as a contraceptive. (<a href="#LINK_efe72f54-72b0-4c42-8f94-ee2d14123c6a">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk">
<li>One tablet taken orally as soon as possible, within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. (<a href="#LINK_3619a89e-0f0b-4478-b712-9a649d75109b">2</a>)</li>
<li>The tablet can be taken with or without food. (<a href="#LINK_3619a89e-0f0b-4478-b712-9a649d75109b">2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disk"><li><p class="Highlighta">30Â mg tabletÂ  (<a href="#LINK_ca07031b-3348-4e45-8cd3-d384c89b57ed">3</a>) </p></li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disk"><li>Known or suspected pregnancy (<a href="#LINK_6b30e0d1-123f-4a4b-aa83-abf10a2c4af3">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>
<span class="Bold">ella</span> is notÂ indicated forÂ termination of an existing pregnancy.Â Exclude pregnancy before administering.Â (<a href="#LINK_e8e1142b-5c5e-47a3-abea-7e08e3d97347">5.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic pregnancy</span>: Women who become pregnant or complain of <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">lower abdominal pain</span> after taking <span class="Bold">ella</span> should be evaluated for <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>. (<a href="#LINK_202a402b-8982-41ad-a391-275e66692316">5.2</a>)</li>
<li>Effect on menstrual cycle: <span class="Bold">ella</span> may alter the next expected menses. If menses is delayed beyond 1 week, pregnancy should be ruled out. (<a href="#LINK_c5c6269f-5b9e-4356-a015-2030f2a5cd3c">5.5</a>)</li>
<li>
<span class="Bold">ella</span> does not protect against STI/HIV. (<a href="#LINK_ae5270ea-cc4d-4627-9fc1-6daec87ad57d">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">The most common adverseÂ reactions (â‰¥ 5%) in the clinical trials were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (18%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (12%),Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (12%), <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> (9%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (6%) and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (5%).Â (<a href="#LINK_ba721b1a-0e0d-4caf-ad22-b85b9e3b8e57">6</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contactÂ Afaxys, Inc. at 1-855-888-2467  or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk"><li>Drugs or herbal products that induce CYP3A4 decrease the effectiveness of <span class="Bold">ella</span>. (<a href="#LINK_85969015-6b96-4b8e-929c-826857efddca">7</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk">
<li>Nursing mothers:Â <span class="Bold">ella </span>is not recommended for use by breastfeeding women.Â (<a href="#LINK_31d0c14f-7449-4f5b-b0bc-6e02774767e9">8.3</a>) 
</li>
<li>
<span class="Bold">ella</span> is not intended for use in premenarcheal (<a href="#LINK_c795ab8a-56c4-45ba-943f-360f59985595">8.4</a>) or postmenopausal women. (<a href="#LINK_0869cf6c-4d7a-49a1-9ec5-204c0482d3ba">8.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">RECENT MAJOR CHANGES</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Existing Pregnancy</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic Pregnancy</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Repeated Use</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 CYP3A4 Inducers</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Fertility Following Use</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Effect on Menstrual Cycle</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Sexually Transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>/HIV</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Changes in Emergency Contraceptive Effectiveness Associated with Co-Administration of Other Products</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Increase in Plasma Concentrations of <span class="Bold">ella</span> Associated with Co-Administered Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Effects of <span class="Bold">ella </span>on Co-Administered Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Race</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Open-Label Study</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Single-Blind Comparative Study</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Pooled Analysis</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="L1afaa68e-14d6-4410-98e5-79c3de11b9c4"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">ella</span> is a progesterone agonist/antagonistÂ emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. <span class="Bold">ella</span> is not intended for routine use as a contraceptive. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_3619a89e-0f0b-4478-b712-9a649d75109b"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Instruct patients to takeÂ one tabletÂ orally as soon as possible within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. </p>
<p>The tablet can be taken with or without food.</p>
<p>If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurs within 3 hours of <span class="Bold">ella</span> intake, consideration should be given to repeating the dose.</p>
<p><span class="Bold">ella </span>can be taken at any time during the menstrual cycle.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_ca07031b-3348-4e45-8cd3-d384c89b57ed"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">The <span class="Bold">ella</span> tablet is supplied as a white to off-white, round, curved tablet containing 30 mg of ulipristal acetate and is marked â€œ<span class="Bold">ella</span>â€? on both sides.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_6b30e0d1-123f-4a4b-aa83-abf10a2c4af3"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">ella</span> is contraindicated for use in the case of known or suspected pregnancy. The risks to a fetus when <span class="Bold">ella</span> is administered to a pregnant woman are unknown. If this drug is inadvertently used during pregnancy, the woman should be apprised of the potential hazard to the fetus. [<span class="Italics">See </span><span class="Italics"><a href="#LINK_160e3ec9-44ed-4bce-8428-9fa71b896018">Use in Specific Populations (8.1</a></span><span class="Italics">).</span>]</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_d7a7cfba-7a14-4173-b582-ba853ae9a086"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e8e1142b-5c5e-47a3-abea-7e08e3d97347"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Existing Pregnancy</h2>
<p class="First"><span class="Bold">ella</span> is not indicated forÂ termination ofÂ an existing pregnancy. Pregnancy should be excluded before prescribing <span class="Bold">ella. </span>If pregnancy cannot be excluded on the basis of history and/or physical examination, pregnancy testing should be performed. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking <span class="Bold">ella</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_202a402b-8982-41ad-a391-275e66692316"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic Pregnancy</span></h2>
<p class="First">A history of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> is not a contraindication to use ofÂ this emergency contraceptive method.Â  Healthcare providers, however, should consider the possibility of <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span> in women who become pregnant or complain of <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">lower abdominal pain</span> after taking <span class="Bold">ella</span>.Â  A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking <span class="Bold">ella</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4b3bf07f-1246-4d9d-9257-7c149d1485c0"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Repeated Use</h2>
<p class="First"><span class="Bold">ella</span> is for occasional use as an emergency contraceptive. It should not replace a regular method of contraception. Repeated use of <span class="Bold">ella</span> within the same menstrual cycle is not recommended, as safety and efficacy of repeat use within the same cycle has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Lb8a6e9b5-c492-42e5-a7c1-d56de1ae1426"></a><a name="section-5.4"></a><p></p>
<h2>5.4 CYP3A4 Inducers</h2>
<p class="First">A CYP3A4 inducer, rifampin, decreases the plasma concentration of ella significantly. <span class="Bold">Ella</span> should not be administered with CYP3A4 inducers <span class="Italics">[see Drug interactions (<a href="#LINK_f4840aa5-c57c-43f0-bc0c-fa5ff110f1ba">7.1</a>) and Pharmacokinetics (<a href="#LINK_aad5d722-ff2f-4387-aff1-9c1a2f271e34">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_94c46528-93c6-49a5-aef1-3597044978d2"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Fertility Following Use</h2>
<p class="First">A rapid return of fertility is likely following treatment with <span class="Bold">ella</span> for emergency contraception; therefore, routine contraception should be continued or initiated as soon as possible following use of <span class="Bold">ella</span> to ensure ongoing prevention of pregnancy. While there are no data about use of <span class="Bold">ella</span> with regular hormonal contraceptives, due to its high affinity binding to the progesterone receptor, use of <span class="Bold">ella</span> mayÂ reduce the contraceptive action of regular hormonal contraceptive methods. Therefore, after use of <span class="Bold">ella</span>, a reliable barrier method of contraception should be used with subsequent acts of intercourse that occur in that same menstrual cycle.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c5c6269f-5b9e-4356-a015-2030f2a5cd3c"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Effect on Menstrual Cycle</h2>
<p class="First">After <span class="Bold">ella</span> intake, menses sometimes occur earlier or later than expected by a few days. In clinical trials, cycle length was increased by a mean ofÂ 2.5 days but returned to normal in the subsequent cycle. Seven percent of subjects reported menses occurring more than 7 days earlier than expected, and 19% reported a delay of more than 7 days. If there is a delay in the onset of expected menses beyond 1 week, rule out pregnancy.</p>
<p>Nine percent of women studied reported <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">intermenstrual bleeding</span> after use of <span class="Bold">ella.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ae5270ea-cc4d-4627-9fc1-6daec87ad57d"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Sexually Transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>/HIV</h2>
<p class="First"><span class="Bold">ella</span> does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) or other sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (STIs).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_ba721b1a-0e0d-4caf-ad22-b85b9e3b8e57"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e140e346-1186-4d5c-807c-f8377b4aef32"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p><span class="Bold">ella</span> was studied in an open-label multicenter trial (Open-Label Study) and in a comparative, randomized, single-blind, multicenter trial (Single-Blind Comparative Study). In these studies, a total of 2,637Â (1,533 + 1,104) women in the 30 mg ulipristal acetate groupsÂ were included in the safety analysis. The mean age of women who received ulipristal acetate was 24.5 years and the mean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) was 25.3. The racial demographics of those enrolled were 67% Caucasian, 20% Black or African American, 2% Asian, and 12% other.Â  </p>
<p>The most common adverseÂ reactions (â‰¥ 10%) in the clinical trials for women receiving <span class="Bold">ella</span> were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (18% overall) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (12% overall) and abdominal and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> (12% overall). Table 1 lists those adverse reactions that were reported in â‰¥ 5% of subjects in the clinical studies (<a href="#LINK_bbde6a83-6905-4ce7-8213-59549b016739">14</a>). </p>
<table>
<caption><span>Table 1: Adverse Reactions in â‰¥Â 5% of Women (%) Receiving a Single Dose of ella (30 mg Ulipristal Acetate)</span></caption>
<col>
<col width="150px">
<col width="150px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><span class="Bold">Most Common Adverse Reactions</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Open-Label StudyÂ </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Â Single-Blind <br>Comparative Study</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Â N = 1,533</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Â N = 1,104</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 18</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 19</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 12</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Abdominal and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 15</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Â <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 7</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 13</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 6</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 5</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d4d1e6c1-a425-4b39-8c40-e816dea38989"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of <span class="Bold">ella:<br></span>Â Â Â Â Â Â Â Â Skin and Subcutaneous TissueÂ Disorders: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span><br><br>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_85969015-6b96-4b8e-929c-826857efddca"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Several <span class="Italics">in vivo</span> drug interaction studies have shown that <span class="Bold">ella</span> is predominantly metabolized by CYP3A4.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f4840aa5-c57c-43f0-bc0c-fa5ff110f1ba"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Changes in Emergency Contraceptive Effectiveness Associated with Co-Administration of Other Products</h2>
<p class="First">Drugs or herbal products that induce CYP3A4 decrease the plasma concentrations of <span class="Bold">ella</span>, and may decrease its effectiveness <span class="Italics">[see Warnings and Precautions (<a href="#Lb8a6e9b5-c492-42e5-a7c1-d56de1ae1426">5.4â€‹</a>) and Pharmacokinetics (<a href="#LINK_aad5d722-ff2f-4387-aff1-9c1a2f271e34">12.3</a>)]</span>. Avoid co-administration of <span class="Bold">ella</span> and drugs or herbal products such as:</p>
<ul class="Disk">
<li>barbiturates</li>
<li>bosentan</li>
<li>carbamazepine</li>
<li>felbamate</li>
<li>griseofulvin</li>
<li>oxcarbazepine</li>
<li>phenytoin</li>
<li>rifampin</li>
<li>St. Johnâ€™s Wort</li>
<li>topiramate</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ae6239bb-dddd-4680-b332-a28ca53e9ef3"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Increase in Plasma Concentrations of <span class="Bold">ella</span> Associated with Co-Administered Drugs</h2>
<p class="First">CYP3A4 inhibitors such as itraconazole or ketoconazole increase plasma concentrations of <span class="Bold">ella </span><span class="Italics">[see Pharmacokinetics (<a href="#LINK_aad5d722-ff2f-4387-aff1-9c1a2f271e34">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0c8c9f93-e7cf-4a30-8f0d-8f0e469e05ed"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Effects of <span class="Bold">ella </span>on Co-Administered Drugs</h2>
<p class="First"><span class="Italics">In vitro</span> studies demonstrated that <span class="Bold">ella</span> does not induce or inhibit the activity of cytochrome P450 enzymes.</p>
<p>P-glycoprotein (P-gp) transporters: <span class="Italics">In vitro</span> data indicate that ulipristal may be an inhibitor of P-gp at clinically relevant concentrations. Thus, co-administration of ulipristal acetate and P-gp substrates (e.g., dabigatran etexilate, digoxin) may increase the concentration of P-gp substrates. <span class="Italics">In vivo</span> data suggest that ulipristal acetate 10 mg does not affect P-gp transporters. However, there was no <span class="Italics">in vivo</span> drug interaction study between ulipristal acetate 30 mg and P-gp transporters [<span class="Italics">see Pharmacokinetics (<a href="#LINK_aad5d722-ff2f-4387-aff1-9c1a2f271e34">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_df7ab56a-7818-41a2-affd-5c4b988dd81a"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_160e3ec9-44ed-4bce-8428-9fa71b896018"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category X. [<span class="Italics">See </span><span class="Italics"><a href="#LINK_6b30e0d1-123f-4a4b-aa83-abf10a2c4af3">Contraindications (4</a></span><a href="#LINK_6b30e0d1-123f-4a4b-aa83-abf10a2c4af3">)</a>.]</p>
<p>Use of <span class="Bold">ella</span> is contraindicated during an existing or suspected pregnancy.<br><br>There are no adequate and well controlled studies in pregnant women.</p>
<p>Ulipristal acetate was administered repeatedly to pregnant rats and rabbits during the period of organogenesis. Embryofetal loss was noted in all pregnant rats and in half of the pregnant rabbitsÂ followingÂ 12 and 13 days of dosing, at dailyÂ drug exposures 1/3Â and 1/2Â the human exposure, respectively, based on body surface area (mg/m<span class="Sup">2</span>). There were no malformations of the surviving fetuses in these studies. Adverse effects were not observed in the offspring of pregnant rats administered ulipristal acetate during the period of organogenesis through lactation at drug exposures 1/24 the human exposure based on AUC. Administration of ulipristal acetate to pregnant monkeys for 4 days during the first trimester caused pregnancy termination inÂ 2/5 animals at daily drug exposures 3 timesÂ the human exposure based on body surface area.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_31d0c14f-7449-4f5b-b0bc-6e02774767e9"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">The breast milk of 12 lactating women following administration of <span class="Bold">ella</span> was collected in 24-hour increments to measure the concentrations of ulipristal acetate and monodemethyl-ulipristal acetate in breast milk. The mean daily concentrations of ulipristal acetate in breast milk were 22.7 ng/mL [0-24 hours], 2.96 ng/mL [24-48 hours], 1.56 ng/mL [48-72 hours], 1.04 ng/mL [72-96 hours], and 0.69 ng/mL [96-120 hours]. The mean daily concentrations of monodemethyl-ulipristal acetate in breast milk were 4.49 ng/mL [0-24 hours], 0.62 ng/mL [24-48 hours], 0.28 ng/mL [48-72 hours], 0.17 ng/mL [72-96 hours], and 0.10 ng/mL [96-120 hours].</p>
<p>The effect of this exposure on newborns/infants has not been studied; therefore, risk to the breast-fed child cannot be excluded. Therefore, use of <span class="Bold">ella </span>by breastfeeding women is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_c795ab8a-56c4-45ba-943f-360f59985595"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy of <span class="Bold">ella</span> have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents less than 18 years and for users 18 years and older. Use of <span class="Bold">ella</span> before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is not indicated. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_0869cf6c-4d7a-49a1-9ec5-204c0482d3ba"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">This product is not intended for use in postmenopausal women. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cd95d227-8c4c-4953-98e3-286142dacaa0"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Race</h2>
<p class="First">While no formal studies have evaluated the effect of race, a cross-study comparison of two pharmacokinetic studies indicated that exposure in South Asians may exceed that in Caucasians and African Americans. However, no difference in efficacy and safety was observed for women of different races in clinical studies.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_814aac4c-94e7-4d44-8c52-554e21029bdc"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No studies have been conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on the disposition of <span class="Bold">ella</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_868b581c-ea7c-4eb5-8762-db077040863c"></a><a name="section-8.7"></a><p></p>
<h2>8.8 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No studies have been conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on the disposition of <span class="Bold">ella</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_023aa5a7-3711-4097-ae80-767bc6f696cb"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Experience with ulipristal acetate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is limited. In a clinical study,Â singleÂ doses equivalent to up toÂ 4 times <span class="Bold">ella </span>were administered to a limited number of subjects without any adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_ab511004-0438-4da8-9246-d122e234d463"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The ella (ulipristal acetate) tablet for oral use contains 30 mg of a single active steroid ingredient, ulipristal acetate [17Î±-acetoxy-11Î²-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione], a synthetic progesterone agonist/antagonist. The inactive ingredients are lactose monohydrate, povidone K-30, croscarmellose sodium and magnesium stearate.</p>
<p>Ulipristal acetate is a white to yellow crystalline powder which has a molecular weight of 475.6. The structural formula is:</p>
<p></p>
<p><img alt="Ulipristal acetate structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=052bfe45-c485-49e5-8fc4-51990b2efba4&amp;name=ella-tablet-1.jpg"></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  C<span class="Sub">30</span>H<span class="Sub">37</span>NO<span class="Sub">4</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_f7a234aa-736b-47fe-8305-863fdffb1aa1"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_87941ecb-926e-4be6-a0bd-03264ea33d7e"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">When taken immediately before ovulation is to occur, <span class="Bold">ella</span>Â postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation mayÂ also contribute to efficacy.Â </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_fbdee23c-a48e-4acf-96b3-7d2f1fb5134c"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Ulipristal acetate is a selective progesterone receptor modulator with antagonistic and partial agonistic effects (a progesterone agonist/antagonist) at the progesterone receptor. It binds the human progesterone receptor and prevents progesterone from occupying its receptor.</p>
<p>The pharmacodynamics of ulipristal acetate depends on the timing of administration in the menstrual cycle. Administration in the mid-follicular phase causesÂ inhibition of folliculogenesis and reduction of estradiol concentration.Â Administration at the time of the luteinizing hormone peak delays follicular rupture by 5 to 9 days. Dosing in the early luteal phase does not significantly delay endometrial maturation butÂ decreases endometrial thickness by 0.6 Â± 2.2 mm (mean Â± SD).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_aad5d722-ff2f-4387-aff1-9c1a2f271e34"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Following a single dose administration of <span class="Bold">ella</span> in 20 women under fasting conditions, maximum plasma concentrations of ulipristal acetate and the active metabolite, monodemethyl-ulipristal acetate, were 176Â and 69 ng/ml and were reached at 0.9 and 1 hour, respectively.Â </p>
<p><span class="Bold">Figure 1: Mean (Â± SD) Plasma Concentration-time Profile of Ulipristal Acetate and Monodemethyl-ulipristal Acetate Following Single Dose Administration of 30 mg Ulipristal Acetate</span></p>
<div class="Figure"><img alt="Figure 1: Mean ((Â± SD) plasma concentration-time profile of ulipristal acetate and monodemethyl-ulipristal acetate following single dose administration of 30 mg ulipristal acetate" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=052bfe45-c485-49e5-8fc4-51990b2efba4&amp;name=ella-tablet-2.jpg"></div>
<table>
<caption><span>Table 2: Pharmacokinetic Parameter Values Following Administration of ella (ulipristal acetate) Tablet 30 mg to 20 Healthy Female Volunteers under Fasting Conditions</span></caption>
<colgroup>
<col width="190px">
<col width="190px">
<col width="190px">
<col width="190px">
<col width="190px">
<col width="190px">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Â Mean (Â± SD)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">C<span class="Sub">max</span><br>(ng/ml)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">AUC<span class="Sub">0-t</span><br>(ngâ€¢hr/ml)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">AUC<span class="Sub">0-âˆž</span><br>(ngâ€¢hr/ml)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">t<span class="Sub">max</span><br>(hr)*</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">t<span class="Sub">1/2</span><br>(hr)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Ulipristal acetate</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">176<br>(89)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">548<br>(259)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">556<br>(260)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0.9<br>(0.5-2.0)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">32<br>(6.3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Monodemethyl-ulipristal acetate</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">69<br>(26)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">240<br>(59)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">246<br>(59)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1.00<br>(0.8-2.0)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">27<br>(6.9)</p></td>
</tr>
</tbody>
</table>
<p>C<span class="Sub">max</span> = maximum concentration<br>AUC<span class="Sub">0-t</span> = area under the drug concentration curve from time 0 to time of last determinable concentration <br>AUC<span class="Sub">0-âˆž</span> = area under the drug concentration curve from time 0 to infinity <br>t<span class="Sub">max</span> = time to maximum concentration <br>t<span class="Sub">1/2</span> = elimination half-life <br>* Median (range)</p>
<p>Effect of food: Administration of <span class="Bold">ella</span> together with a high-fat breakfast resulted in approximately 40-45% lower mean C<span class="Sub">max</span>, a delayed t<span class="Sub">max</span> (from a median of 0.75Â hours to 3Â hours) and 20-25% higher mean AUC<span class="Sub">0-âˆž</span> ofÂ ulipristal acetateÂ and monodemethyl-ulipristal acetate compared with administration in the fasting state.Â These differences are not expected to impair the efficacy or safety of <span class="Bold">ella</span> to a clinically significant extent; therefore, <span class="Bold">ella</span> can be taken with or without food.</p>
<p><span class="Underline">Distribution</span></p>
<p>Ulipristal acetate is highly bound (&gt; 94%) to plasma proteins, including high density lipoprotein,Â alpha-l-acid glycoprotein, andÂ albumin.</p>
<p><span class="Underline">Metabolism </span></p>
<p>Ulipristal acetate is metabolized to mono-demethylated andÂ di-demethylated metabolites. <span class="Italics">In vitro</span> data indicate that this is predominantly mediated by CYP3A4. The mono-demethylated metabolite is pharmacologically active.</p>
<p><span class="Underline">Excretion</span></p>
<p>The terminal half-life of ulipristal acetate in plasma following a single 30Â mg dose is estimated to 32.4 Â± 6.3Â hours.Â </p>
<p><span class="Underline">Drug interactions</span></p>
<p><span class="Bold">CYP3A4 inducers: </span>When a single 30 mg dose of ulipristal acetate was administered following administration of the strong CYP3A4 inducer, rifampin 600 mg once daily for 9 days, C<span class="Sub">max</span> and AUC of ulipristal acetate decreased by 90% and 93% respectively. The C<span class="Sub">max</span> and AUC of monodemethyl-ulipristal acetate decreased by 84% and 90% respectively <span class="Italics">[see Drug Interactions (<a href="#LINK_f4840aa5-c57c-43f0-bc0c-fa5ff110f1ba">7.1</a>)]</span>.</p>
<p><span class="Bold">CYP3A4 inhibitors: </span>When a single 10 mg dose of ulipristal acetate was administered following administration of the strong CYP3A4 inhibitor, ketoconazole 400 mg once daily for 7 days, C<span class="Sub">max</span> and AUC of ulipristal acetate increased by 2- and 5.9- fold, respectively. While the AUC of monodemethyl-ulipristal acetate increased by 2.4-fold, C<span class="Sub">max</span> of monodemethyl-ulipristal acetate decreased by 47%. There was no <span class="Italics">in vivo</span> drug-drug interaction study between ulipristal acetate 30 mg and CYP3A4 inhibitors <span class="Italics">[see Drug Interactions (<a href="#LINK_f4840aa5-c57c-43f0-bc0c-fa5ff110f1ba">7.1</a>)]</span>.</p>
<p><span class="Bold">P-glycoprotein (P-gp) transporters</span>: When a single 60 mg dose of fexofenadine, a substrate of P-gp glycoprotein, was administered 1.5 hours after the administration of a single 10 mg dose of ulipristal acetate, there was no increase in C<span class="Sub">max</span> or AUC of fexofenadine.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_7b7713d7-49c1-4699-9ca9-e1600dcb60c5"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_d0267acd-4def-4591-9cc7-1b9228e267f4"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity: Carcinogenicity studies with ulipristal acetate have not been conducted.</p>
<p>Genotoxicity: Ulipristal acetate was not genotoxic in the Ames assay, <span class="Italics">in vitro</span> mammalian assays utilizing mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells and human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and in an<span class="Italics"> in vivo</span>Â micronucleus assay in mice.Â </p>
<p>Impairment of Fertility: Single oral doses of ulipristal acetate prevented ovulation in 50% of rats at 2 times the human exposure based on body surface area (mg/m<span class="Sup">2</span>). Single doses of ulipristal acetate given on post-coital days 4 or 5 prevented pregnancy in 80 - 100% of rats and in 50% of rabbits when given on post-coital days 5 or 6 at drug exposures 4 and 12 times the human exposure based on body surface area. Lower doses administered forÂ 4 days to rats and rabbits were also effective at preventing ovulation and pregnancy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_bbde6a83-6905-4ce7-8213-59549b016739"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Two multicenter clinical studiesÂ evaluated the efficacy and safety of <span class="Bold">ella</span>.Â An open-label studyÂ provided the primary data to support the efficacy and safety of ulipristal acetate for emergency contraception when taken 48 to 120 hours after unprotected intercourse.Â A single-blind comparative studyÂ provided the primary data to support the efficacy and safety of ulipristal acetate for emergency contraception when taken 0 to 72 hours after unprotected intercourse andÂ provided supportive data for ulipristal acetate for emergency contraception when taken &gt; 72 to 120 hours after unprotected intercourse. Women in both studies were required to have a <span class="product-label-link" type="condition" conceptid="4094448" conceptname="Pregnancy test negative">negative pregnancy test</span> prior to receiving emergency contraception. The primary efficacy analyses were performed on subjects less than 36 years of age who had a known pregnancy status after taking study medication.</p>
<table>
<caption><span>Table 3: Summary of Clinical Trial Results for Women Who Received a Single Dose of ella (30 mg Ulipristal Acetate)</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Open-Label Study <br>48 to 120 Hours*</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Â Single-Blind Comparative Study <br>0 to 72 Hours*</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Â N = 1,242</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â N = 844</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Expected Pregnancy Rate**</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 5.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 5.6</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Observed Pregnancy Rate**<br>(95% confidence interval)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 2.2<br>(1.5, 3.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.9<br>(1.1, 3.1)</td>
</tr>
</tbody>
</table>
<p>* Time after unprotected intercourse when <span class="Bold">ella</span> was taken<br>**Number of pregnancies per 100 women at risk for pregnancy</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8aef0c12-dc09-4c57-9370-cea1007c20e4"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Open-Label Study</h2>
<p class="First">This study was a multicenter open-label trial conducted at 40 family planning clinics in the United States. Healthy women with a mean age of 24 years who requested emergency contraception 48 to 120 hours after unprotected intercourse received a dose of 30 mg ulipristal acetate (<span class="Bold">ella</span>). The median BMI for the study subjects wasÂ 25.3 and ranged from 16.1 to 61.3 kg/m<span class="Sup">2</span>.</p>
<p>Twenty-seven pregnancies occurred in 1,242 women aged 18 to 35 years evaluated for efficacy.Â The number of pregnancies expected without emergency contraception wasÂ calculated based on the timing of intercourse with regard to each womanâ€™s menstrual cycle. <span class="Bold">ella</span> statistically significantly reduced the pregnancy rate, from an expected rate of 5.5% to an observed rate of 2.2%, when taken 48 to 120 hours after unprotected intercourse.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c7013638-0e43-4a3d-ab7e-1323bb28c0d1"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Single-Blind Comparative Study</h2>
<p class="First">This study was a multicenter, single-blind, randomized comparison of the efficacy and safety of 30 mg ulipristal acetate (<span class="Bold">ella</span>) to levonorgestrel (another form of emergency contraception). Subjects were enrolled atÂ 35 sites in the U.S., the United Kingdom and Ireland, withÂ the majority (66%) having been enrolled in the U.S. Healthy womenÂ with a mean age of 25 years who requested emergency contraception within 120 hours of unprotected intercourse were enrolled and randomly allocated to receive <span class="Bold">ella</span> or levonorgestrel 1.5 mg. The median BMI for the study subjects was 25.3 and ranged from 14.9 to 70.0 kg/m<span class="Sup">2</span>.Â  </p>
<p>In the <span class="Bold">ella</span> group, 16 pregnancies occurred inÂ 844 women aged 16 to 35 years when emergency contraception was taken 0 to 72 hours after unprotected intercourse.Â The number of pregnancies expected without emergency contraceptionÂ was calculated based on the timing of intercourse with regard to each womanâ€™s menstrual cycle; <span class="Bold">ella</span> statistically significantly reduced the pregnancy rate, from an expected 5.6% to an observed 1.9%, when taken within 72 hours after unprotected intercourse. There were no pregnancies observed in the women who were administered <span class="Bold">ella</span> more thanÂ 72 hours after unprotected intercourse (10% of women who received <span class="Bold">ella</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e5406070-6c04-4b74-ac9f-81aaf17e0dde"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Pooled Analysis</h2>
<p class="First">Data from the two studies were pooled to provide a total efficacy population of women treated with ulipristal acetate up to 120 hours after UPI. Time Trend analysis for the five 24-hour intervals from 0 to 120 hours between unprotected intercourse and treatment was conducted. There were no significant differences in the observed pregnancy rates across the five time intervals. </p>
<p>Subgroup analysis of the pooled data by BMI showed that for women with BMI &gt; 30 kg/m<span class="Sup">2</span>Â (16% of all subjects), the observed pregnancy rate was 3.1% (95% CI: 1.7, 5.7), which was not significantly reduced compared to the expected pregnancy rate of 4.5% in the absence of emergency contraception taken within 120 hours after unprotected intercourse. In the comparative study, a similar effect was seen for the comparator emergency contraception drug, levonorgestrel 1.5 mg. For levonorgestrel, when used by women with BMI &gt; 30 kg/m<span class="Sup">2</span>, the observed pregnancy rate was 7.4% (95% CI: 3.9, 13.4), compared to the expected pregnancy rate of 4.4% in the absence of emergency contraception taken within 72 hours after unprotected intercourse.Â </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_2fd58334-d034-407e-8f6e-5384913e6e07"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">ella</span> (ulipristal acetate) tablet, 30 mg is supplied in a PVC-PE-PVDC-aluminum <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. The tablet is a white to off-white, round, curved tablet marked with "<span class="Bold">ella</span>" on both sides.Â </p>
<p>NDC 50102-911-01 (1 tablet unit of use package)</p>
<p>Store at 20-25Â°C (68-77Â°F). [See USP controlled room temperature.]</p>
<p>Keep the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> in the outer carton in order to protect from light. <span class="Bold">Keep out of reachÂ of children</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_14c24d58-b6a0-4ba7-bf4f-7d5ecc689a82"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">[See FDA-Approved Patient Labeling]</span></p>
<p><span class="Bold">Information for Patients</span></p>
<ul class="Disk">
<li>Instruct patients to take <span class="Bold">ella</span> as soon as possible and not more than 120 hours after unprotected intercourse or a known or suspected contraceptive failure.</li>
<li>Advise patients thatÂ they should not take <span class="Bold">ella</span> if they know or suspect they are pregnant and that <span class="Bold">ella </span>is not indicated for termination of an existing pregnancy.</li>
<li>Advise patients to contact their healthcare provider immediately in case ofÂ vomitingÂ withinÂ 3 hours of taking the tablet,Â to discuss whether to take another tablet.</li>
<li>Advise patients to seek medical attention if they experience severe <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">lower abdominal pain</span> 3 to 5 weeks after taking <span class="Bold">ella</span>, in order to be evaluated for an <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>.</li>
<li>Advise patients to contact their healthcare provider andÂ consider the possibility of pregnancy if their period is delayed after taking <span class="Bold">ella </span>by more than 1 week beyond the dateÂ it wasÂ expected.</li>
<li>Advise patients not toÂ use <span class="Bold">ella</span> as routine contraception, or to use it repeatedly in the same menstrual cycle.</li>
<li>Advise patients that <span class="Bold">ella</span> may reduce the contraceptive action of regular hormonal contraceptive methods and to use a reliable barrier method of contraception after using <span class="Bold">ella, </span>for any subsequent acts of intercourse that occur in that same menstrual cycle. </li>
<li>Advise patients not to use <span class="Bold">ella</span> if they are taking a CYP3A4 inducer.</li>
<li>Inform patients that <span class="Bold">ella</span> does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</li>
<li>Advise patients that they should not useÂ <span class="Bold">ella</span> if they are breastfeeding because <span class="Bold">ella </span>enters the breast milk.Â </li>
</ul>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="LINK_83637ff8-9c32-4156-98c7-21237387614c"></a><a name="section-16"></a><p></p>
<h1><span class="Bold">Â FDA Approved Patient Labeling</span></h1>
<table width="669px">
<colgroup><col></colgroup>
<tbody class="Headless"><tr class="First Last"><td align="center">
<span class="Bold">Patient Information<br>ella</span> ("el-uh")<br><span class="Bold">(ulipristal acetate) tablet</span>
</td></tr></tbody>
</table>
<p class="First">Read this Patient Information Leaflet before you take<span class="Bold"> ella.Â  </span>There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.Â </p>
<p><span class="Bold">What is ella?</span></p>
<p><span class="Bold">ella</span> is a prescription emergency contraceptive that reduces your chance of becoming pregnant if your birth control fails or you have unprotected sex. <br><br><span class="Bold">ella </span>should not be used as your regular birth control.Â It is very important that you have a reliable form of birth control that is right for you.Â  <br><span class="Bold"><br>ella</span> will not protect you against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> (STDs).</p>
<p><span class="Bold">Who should not take ella?</span></p>
<ul class="Disk">
<li>Do not take <span class="Bold">ella </span>if you know or suspect you are already pregnant.Â  <span class="Bold">ella</span> is not for use to end an existing pregnancy.Â  Talk to your healthcare provider before taking <span class="Bold">ella</span> if you think you are pregnant.Â  </li>
<li>Do not take <span class="Bold">ella</span> if you are breastfeeding because <span class="Bold">ella</span> gets into the breast milk.</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking ella?</span></p>
<p>See "Who should not take <span class="Bold">ella</span>?"<br><br>Tell your healthcare provider about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.<br></p>
<p>Using some other medicines may make <span class="Bold">ella</span> less effective.Â  These include St. Johnâ€™s Wort, phenytoin, rifampin, phenobarbital and carbamazepine.Â  Talk to your healthcare provider about whether <span class="Bold">ella</span> is right for you if you are currently using these medications.</p>
<p></p>
<p>Talk to your healthcare provider if you use hormonal birth control. Using <span class="Bold">ella</span> may make your regular hormonal birth control method less effective. After using <span class="Bold">ella</span>, you should use a reliable barrier method of birth control (such as a condom with spermicide) during any other times that you have sex in that same menstrual cycle.<br><br>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">When is it not appropriate to use ella?</span></p>
<ul class="Disk">
<li>Do not use <span class="Bold">ellaÂ </span>as a regular birth controlÂ method. It does not work as well as most other forms of birth control when they are used consistently and correctly.</li>
<li>Do not use <span class="Bold">ella</span> if you are already pregnant.</li>
<li>Do not use <span class="Bold">ella</span> more than one time in the same menstrual cycle for different acts of unprotected sex orÂ birth control failure.Â </li>
</ul>
<p><span class="Bold">How does ella work?</span><span class="Bold">ella </span>is thought to work for emergency contraception primarily by stopping or delaying the release of an egg from the ovary. It is possible that <span class="Bold">ella</span> may also work by preventing attachment (implantation) to the uterus.</p>
<p><span class="Bold">HowÂ should IÂ take ella?</span></p>
<ul class="Disk">
<li>Take <span class="Bold">ellaÂ </span><span class="Underline">as soon as possible</span> within 5 days (120Â hours) after unprotected sex or if you had a birth control failure.</li>
<li>
<span class="Bold">ella</span> canÂ be taken with or without food.</li>
<li>Contact your healthcare provider right away if you vomit withinÂ 3 hours of taking <span class="Bold">ella.</span>Â Your healthcare provider may prescribe another dose of <span class="Bold">ella</span> for you.</li>
<li>
<span class="Bold">ellaÂ </span>can be taken at any time during the menstrual cycle.</li>
</ul>
<p><span class="Bold">How effective is ella?</span></p>
<p>If <span class="Bold">ella</span> is taken as directed, it will reduce the chance that you will get pregnant.Â <span class="Bold">ella</span> is not effective in every case. <span class="Bold">ella </span>is only to be usedÂ for a single episode of unprotected intercourse. Be sure to use a regular birth control method the next time you have sex.<br><br><span class="Bold">ella </span>and other emergency contraceptives may be less effective in women with a body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) &gt; 30 kg/m<span class="Sup">2</span>.</p>
<p><span class="Bold">What if I am already pregnant and use ella?</span></p>
<p><span class="Bold">ella</span>Â should not be taken if you are already pregnant. There is little information on whether <span class="Bold">ellaÂ </span>would harm a developing baby. Contact your healthcare provider if you think you may be pregnant and have taken <span class="Bold">ella</span>. <br><br><span class="Bold">ella</span> is not for use to terminate an existing pregnancy.</p>
<p><span class="Bold">What should I do if my menstrual period is delayed beyond 1 week or I have severe lower stomach (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>?</span></p>
<p>After taking <span class="Bold">ella</span>, your next menstrual period may begin a few days earlier or later than expected. If your period is more than 7 days later than expected, you may be pregnant. You should get a pregnancy test and follow up with your healthcare provider.<br><br>If you have severe lower stomach (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> about 3 to 5 weeks after taking <span class="Bold">ella</span>, you may have a pregnancy outside of the uterus (womb), which isÂ called an ectopic or <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">tubal pregnancy</span>. An ectopicÂ pregnancy is a serious condition that needs medical treatment right away. Call yourÂ healthcare provider or go to the nearest emergency room right away if you think you may have an <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">ectopic pregnancy</span>.</p>
<p><span class="Bold">How often can I use </span><span class="Bold">ella? </span></p>
<p><span class="Bold">ella</span> is meant for emergency contraception only, and is not to be used frequently or as a regular birth control.Â If youÂ need to use emergency contraception often,Â talk to your healthcare provider and learn about methods for birth control and <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted disease</span> prevention that are right for you.</p>
<p><span class="Bold">What are the possible side effects of ella?</span></p>
<p>The most common side effects of <span class="Bold">ella</span> include:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>stomach (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li>menstrual <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (<span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
<p>Some women taking <span class="Bold">ella </span>may haveÂ their nextÂ period earlier or later than expected. If your period is more than a week late, you should get a pregnancy test. <br><br>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.<br><br>These are not all the possible side effects of <span class="Bold">ella</span>. For more information, ask your healthcare provider or pharmacist.<br><br>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store ella?</span></p>
<ul class="Disk">
<li>Store <span class="Bold">ella </span>atÂ 68-77Â°F (20-25Â°C).</li>
<li>Protect <span class="Bold">ella </span>from light. Keep <span class="Bold">ella </span>in the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card inside the original box until you are ready to take it.</li>
</ul>
<p>Do not use <span class="Bold">ella</span>Â if the package is torn or broken.<br><br>Keep <span class="Bold">ella</span>Â and all medicines out of the reach of children.</p>
<p><span class="Bold">General information about the safe and effective use of ella:</span></p>
<p>Medicines are sometimes prescribed for purposes other than those in a Patient Information Leaflet. Do not use <span class="Bold">ella</span> for a condition for which it was not prescribed. Do not give <span class="Bold">ella</span> to other people, even if they have the same symptoms that you have. It may harm them.<br><br>In the case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, get medical help or contact a Poison Control Center right away at 1-800-222-1222. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> experience with <span class="Bold">ella</span> is limited.</p>
<p>This Patient Information Leaflet summarizes the most important information about <span class="Bold">ella.</span> If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about <span class="Bold">ella</span> that is written for health professionals.</p>
<p>For more information, go to <span class="Italics"><a href="#www.ella-rx.com">www.ella-rx.com</a></span> or you can contactÂ Afaxys, Inc. Medical Communications at 1-855-888-2467.</p>
<p><span class="Bold">What are the ingredients in ella?</span><span class="Bold">Active ingredients:</span>Â  ulipristal acetate, 30 mg<br><span class="Bold">Inactive ingredients:</span>Â  lactose monohydrate, povidone,Â croscarmellose sodium, andÂ magnesium stearate</p>
<p>For all medical inquiries contact:<br>Afaxys, Inc.<br>Medical Communications<br>Charleston, SC, 29403, USA<br>1-855-888-2467</p>
<p>Distributed By:<br>Afaxys, Inc.<br>Charleston, SC, 29403, USA</p>
<p>Under License From:<br>Laboratoire HRA Pharma<br>75003 Paris, France</p>
<p><span class="Bold">ella</span><span class="Sup">Â®</span> is a registered trademark <br>of Laboratoire HRA Pharma</p>
<p>Manufactured By:<br>Cenexi, 95520 Osny, France</p>
<p>or<br>Laboratorios LeÃ³n Farma S.A.,Â 24008 LeÃ³n, Spain</p>
<p>or<br>Delpharm Lille SAS, 59390 Lys-Lez-Lannoy, France</p>
<p>Content Updated: June 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_b275819a-49ae-416b-b8ee-94f770e5904c"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">ellaÂ® (ulipristal acetate) tablet 30 mg<br>NDC 50102-911-01<br>Carton x 1 tablet</p>
<p><img alt="ellaÂ® (ulipristal acetate) tablet 30 mg NDC 50102-911-01 Carton x 1 tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=052bfe45-c485-49e5-8fc4-51990b2efba4&amp;name=ella-tablet-3.jpg"></p>
<p></p>
<p><img alt="ellaÂ® (ulipristal acetate) tablet 30 mg NDC 50102-911-01 Carton x 1 tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=052bfe45-c485-49e5-8fc4-51990b2efba4&amp;name=ella-tablet-4.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ELLAÂ 		
					</strong><br><span class="contentTableReg">ulipristal acetate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50102-911</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ULIPRISTAL ACETATE</strong> (ULIPRISTAL) </td>
<td class="formItem">ULIPRISTAL ACETATE</td>
<td class="formItem">30Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ella</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50102-911-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022474</td>
<td class="formItem">08/13/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Afaxys Inc.
							(832701960)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Laboratoire HRA Pharma (502511996)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Crystal Pharma, SAU</td>
<td class="formItem"></td>
<td class="formItem">563371111</td>
<td class="formItem">api manufacture(50102-911), api/fdf analytical testing(50102-911), pack(50102-911)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Laboratorios Leon Farma S.A.</td>
<td class="formItem"></td>
<td class="formItem">467782459</td>
<td class="formItem">fdf manufacture(50102-911), api/fdf analytical testing(50102-911), pack(50102-911)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7707de81-9aab-49fa-bb24-4df95f84eed2</div>
<div>Set id: 052bfe45-c485-49e5-8fc4-51990b2efba4</div>
<div>Version: 2</div>
<div>Effective Time: 20140701</div>
</div>
</div>Â <div class="DistributorName">Afaxys Inc.</div></p>
</body></html>
